Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine

Lasmiditan, a serotonin 5-HT(1F) receptor agonist, was effective for acute treatment of patients with migraine in a phase 3 double-blind randomized controlled study. The current study was designed to replicate these findings in a generalizable population of patients with migraine, including those wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Goadsby, Peter J, Wietecha, Linda A, Dennehy, Ellen B, Kuca, Bernice, Case, Michael G, Aurora, Sheena K, Gaul, Charly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6620826/
https://www.ncbi.nlm.nih.gov/pubmed/31132795
http://dx.doi.org/10.1093/brain/awz134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6620826/
https://www.ncbi.nlm.nih.gov/pubmed/31132795
http://dx.doi.org/10.1093/brain/awz134

Ejemplares similares